Daewoong PharmaceuticalãERS 2026ã«ãŠIPFæ²»çè¬åè£ããã«ã·ããã·ã³ãã®ã°ããŒãã«ç¬¬2çžèšåºè©Šéšã«ãããæ£è 104åã®ããŒã¹ã©ã€ã³ç¹æ§ãçºè¡š
- ç±³åœããã³éåœã§104åã®IPFæ£è ãç»é²ãããã°ããŒãã«ç¬¬2çžèšåºè©Šéšã¯å®äºã«åããŠé²è¡äž
- æç·ç¶åè¬ã®æäžæ£è ããã³éæäžæ£è ã®åæ¹ã察象ã2027幎äžåæã«ãããã©ã€ã³ããŒã¿ãçºè¡šäºå®
- IPFã®æ°ããªæ²»çéžæè¢ãšããŠéçºãé²ããã¡ãŒã¹ãã»ã€ã³ã»ã¯ã©ã¹ã®PRSé»å®³è¬
ãã«ã»ããïŒã¹ãã€ã³ïŒããã³ãœãŠã«ïŒéåœïŒã2026幎9æ24æ¥ /PRNewswire/ -- Daewoong PharmaceuticalïŒå ±åCEOïŒSeongsoo ParkãChangjae LeeïŒã¯ãã¹ãã€ã³ã®ãã«ã»ããã§9æ6æ¥ïŒçŸå°æéïŒã«éå¬ãããæ¬§å·åŒåžåšåŠäŒïŒERSïŒ2026幎ç·äŒã«ãããŠãç¹çºæ§èºç·ç¶çïŒIPFïŒæ²»çè¬åè£ããã«ã·ããã·ã³ïŒBersiporocinãéçºã³ãŒãïŒDWN12088ïŒãã®ã°ããŒãã«ç¬¬2çžèšåºè©Šéšã«ç»é²ãããå š104åã®æ£è ã®ããŒã¹ã©ã€ã³ç¹æ§ã«é¢ãããã¹ã¿ãŒçºè¡šã宿œãããšçºè¡šããŸããã
ç¹çºæ§èºç·ç¶çã¯ãããŸããŸãªççæ§ããã³ç·ç¶åã·ã°ãã«ãçžäºäœçšããã³ã©ãŒã²ã³ã®éå°ãªç£çãšèç©ãåŒãèµ·ããçŸæ£ã§ããDaewoong Pharmaceuticalãéçºãé²ããŠãããã«ã·ããã·ã³ã¯ããããªã«tRNAåæé µçŽ ïŒPRSïŒãéžæçã«é»å®³ããããšã§ãç·ç¶åã«äŒŽãéå°ãªã³ã©ãŒã²ã³ç£çãæå¶ããŸãã
ãã«ã·ããã·ã³ã¯ãPRSé»å®³ãéããŠè€æ°ã®ç·ç¶åä¿é²ã·ã°ãã«ã®äžæµã«ããã³ã©ãŒã²ã³åæãæšçãšãããå·®å¥åãããäœçšæ©åºãæããŠããŸãããã®ç¬èªã®äœçšæ©åºã«åºã¥ããæç·ç¶åè¬ã«ããèæ¯æ²»çãåããŠããæ£è ãšåããŠããªãæ£è ã®åæ¹ã«ãããŠè©äŸ¡ãé²ããããŠããŸãã
æ¬çºè¡šã§ã¯ãéåœããã³ç±³åœã§ç»é²ããããã¹ãŠã®IPFæ£è ã«ãããããŒã¹ã©ã€ã³æã®èšåºçããã³æ©èœçç¹åŸŽãåæããŸãããKATRDIC 2025ã§ã®ç»é²äžéããŒã¿ã®çºè¡šã«ç¶ããDaewoong Pharmaceuticalã¯ERS 2026ã«ãããŠãç»é²ãå®äºããå šæ£è éå£ã®ããŒã¹ã©ã€ã³ããŒã¿ãåããŠçºè¡šããŸããã
åæã®çµæãå š104åã®æ£è ã®ãã¡ã55åïŒ52.9%ïŒãéåœã49åïŒ47.1%ïŒãç±³åœã§ã®ç»é²ã§ããããšã瀺ãããŸãããå šäœã®71åïŒ68.3%ïŒãæç·ç¶åè¬ã«ããèæ¯æ²»çãåããŠããã®ã«å¯Ÿãã33åïŒ31.7%ïŒã¯åããŠããŸããã§ãããåªåæ§èºæŽ»éïŒFVCïŒã®å¹³åå€ã¯äºæž¬å€ã®çŽ77%ãäžé žåççŽ èºæ¡æ£èœïŒDLCOïŒã®å¹³åå€ã¯äºæž¬å€ã®çŽ51%ã§ãããå šäœãšããŠãæç·ç¶åè¬ã«ããèæ¯æ²»çã®æç¡ã«ããããããæ£è éã®ããŒã¹ã©ã€ã³æã®èšåºçããã³æ©èœçç¹åŸŽã¯æŠãåçã§ããã
çŸåšé²è¡äžã®ã°ããŒãã«ç¬¬2çžèšåºè©Šéšã¯ãéåœããã³ç±³åœã§å®æœãããŠããç¡äœçºåäºéç²æ€ãã©ã»ãå¯Ÿç §è©Šéšã§ããæ£è ã¯ãã«ã·ããã·ã³ãŸãã¯ãã©ã»ãã1æ¥2åã24é±éã«ãããæäžããããã«ãã§ããã³ãŸãã¯ãã³ããããã®äœµçšãèªããããŠããŸããæ¬è©Šéšãã¶ã€ã³ã¯ãæç·ç¶åè¬ã«ããèæ¯æ²»çãåããŠããæ£è ãšåããŠããªãæ£è ã®åæ¹ãçµã¿å ¥ããããšã§ãå®éã®IPF蚺ççŸå Žãåæ ããŠããŸãã
ãã®ããŒã¹ã©ã€ã³åæã¯ã第2çžèšåºè©Šéšã«ãããæå¹æ§ããã³å®å šæ§ã®çµæãè§£éããäžã§éèŠãªèæ¯æ å ±ãšãªããŸããDaewoong Pharmaceuticalã¯ã2027幎äžåæã«ç¬¬2çžèšåºè©Šéšã®ãããã©ã€ã³çµæãçºè¡šããäºå®ã§ãã
äžæ¹ããã«ã·ããã·ã³ã¯ç±³åœé£åå»è¬åå±ïŒFDAïŒããåžå°çŸç çšå»è¬åæå®ããã³ãã¡ã¹ããã©ãã¯æå®ãååŸããŠããã»ããæ¬§å·å»è¬ååºïŒEMAïŒãããåžå°çŸç çšå»è¬åæå®ãåããŠãããã°ããŒãã«éçºãå éãããŠããŸãã
æ¬è©Šéšã«åå ããSeverance HospitalåŒåžåšå ç§ã®Moo Suk Parkææã¯ããæ¬è©Šéšã¯ãéåœããã³ç±³åœã§ç»é²ãããIPFæ£è 104åã®ããŒã¹ã©ã€ã³ç¹æ§ãå æ¬çã«ç¶²çŸ ãããã®ã§ãããšè¿°ã¹ãŸããããæ¬è©Šéšã«ã¯ãæç·ç¶åè¬ã«ããèæ¯æ²»çãåããŠããæ£è ãšåããŠããªãæ£è ã®åæ¹ãå«ãŸããŠããããããããã®ããŒã¹ã©ã€ã³ããŒã¿ã¯ããã«ã·ããã·ã³ã®æå¹æ§ããã³å®å šæ§ã®çµæãè§£éããäžã§éèŠãªèæ¯æ å ±ãæäŸããŸããã
Daewoong Pharmaceuticalã®CEOã§ããSeongsoo Parkæ°ã¯ããã°ããŒãã«ç¬¬2çžèšåºè©Šéšã®æ£è ç»é²ãå®äºããERS 2026ã«ãããŠæ£è å šäœã®ããŒã¹ã©ã€ã³ãããã¡ã€ã«ãå ±æã§ããããšã¯ããã«ã·ããã·ã³ã®éçºã«ãããæ¥µããŠéèŠãªãã€ã«ã¹ããŒã³ãšãªããŸãããšè¿°ã¹ãŸããããåœç€Ÿã¯ã2027幎äžåæã®ç¬¬2çžèšåºè©Šéšãããã©ã€ã³çµæã«åããŠæ¬ããã°ã©ã ã®éçºãçå®ã«æšé²ããåŸãããç¥èŠããã®åŸã®ã°ããŒãã«éçºã«åœ¹ç«ãŠãŠãŸãããŸããã

[Photo1] Professor Moo Suk Park of the Department of Pulmonology at Severance Hospital presents the baseline patient profile analysis from the global Phase 2 trial of Bersiporocin at ERS 2026.
[åè]
https://drive.google.com/file/d/1XSXImvc5mcgdoSozP_B4BnDlsTW7Pfz_/view
ãã¹ã¿ãŒãžã®ãªã³ã¯ïŒãPRSé»å®³è¬ãã«ã·ããã·ã³ã®ç»é²å®äºã°ããŒãã«ç¬¬2çžèšåºè©Šéšã«ãããç¹çºæ§èºç·ç¶çæ£è
ã®ããŒã¹ã©ã€ã³èšåºçã»æ©èœçã¹ãã¯ãã©ã ã
ããããèšäº









ã³ã¡ã³ã (0)
$ãã¿ã³ãã¯ãªãã¯ããã·ã³ãã«ãå ¥åããŠãæ ªåŒãETFããŸãã¯ãã®ä»ã®ãã£ãã«ãŒã·ã³ãã«ããªã³ã¯ããŸãã